软肝冲剂对肝硬化患者外周血单核细胞TGF-β1IFN-γ和IL-8 mRNA表达的影响

Effect of ruanganchengji on PBMN expression levels of TGF-β1 IFN-γ and IL-18 mRNA in patients with cirrhosis

目的:观察软肝冲剂治疗前后肝硬化(LC)患者外周血单核细胞(PBMC)中转化生长因子(TGF-β1)、干扰素-γ(IFN-γ)和白介素18(IL-18)的mRNA表达及分泌水平的变化。探讨软肝冲剂对肝硬化治疗的作用机制。方法:RT-PCR检测20例正常对照组和25例肝硬化患者软肝冲剂治疗前、治疗2、4、6月后PBMC中TGF-β1、IFN-γ和IL-8的mRNA表达水平;ELISA法检测PHA体外诱生PBMC培养上清中TGF-β1、IFN-γ和IL-18分泌水平。结果:肝硬化患者PBMC中的TGF-β1 mRNA表达水平及TGF-β1分泌水平显著高于对照组(P<0.01)。而IFN-γ和IL-18的mRNA表达水平及IFN-γ和IL-18分泌水平显著低于对照组(P<0.01)。经软肝冲剂治疗后,TGF-β1 mRNA表达水平及分泌水平逐渐下降,6个月后与治疗前相比有显著差异(P<0.01),但仍高于对照组;IFN-γ和IL-18的mRNA表达水平及IFN-γ和IL-18分泌水平逐渐上升,6个月后与治疗前相比有显著差异(P<0.01),但仍低于对照组。结论:软肝冲剂能通过下调PBMC中TGF-β1 mRNA和上调IFN-γ和IL-8 mRNA表达,对肝硬化有较好的疗效。

Objective：To study the changes of TGF-β1 mRNA, IFN-γ mRNA and IL-18mRNA in the peripheral blood mononuclear cells （PBMC） of patients with liver cirrhosis （LC） treated with Ruanganchengji. Method： 25 patients with liver cirrhosis were treated by Ruanganchengji. At different time （before therapy, and 2 months, 4 months and 6 months after therapy）, The expression level of TGF-β1, IFN-γ,IL-18 mRNA in PBMC between LC group and control group （20） were measured by RT-PCR. The cytokines＇ Concentrations of TGF -β1, IFN-γ,IL-18 in PBMC in duced by phytohemagglutinin （PHA） were detected by ELISA. Result;The expression level of TGF-β1 mRNA in LC patients PBMC group was higher prominently than control PBMC group （P〈0. 001）. but the expression level of IFN-γ, IL-18 mRNA in LC patients PBMC group was lower prominently than control PBMC group （P〈0. 001）. After treated by Ruanganchengji, the expression level of TGF-β1 mRNA decreased gradually. It was lower prominently at 6 months than it was before therapy （P〈0. 001） . But it was still higher than that of control group（P〈0.011. The expression level of IFN-γ,IL-18 mRNA increased gradually. It was higher prominently at 6 months than it was before therapy（P〈0.01）. But it was still lower than that of control group （P〈0. 01）. Furthermore The Concentrations of TGF-β1, IFN-γ, IL-18 secreted by PBMC in duced by PHA also con firmed the same results. Conclusion： Ruanganchengji could treat Live cirrhosis through the decrease of the expres sion level of TGF-β1 mRNA and increase of that of IFN-γ,IL-18 mRNA in patients with Live cirrhosis.